Ashish Sangal

662 total citations
19 papers, 464 citations indexed

About

Ashish Sangal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ashish Sangal has authored 19 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Ashish Sangal's work include Cancer Genomics and Diagnostics (5 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Ashish Sangal is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Ashish Sangal collaborates with scholars based in United States and Cuba. Ashish Sangal's co-authors include Glen J. Weiss, Vivek Khemka, Cynthia A. Lynch, Jiaxin Niu, John Farley, Lisa Blaydorn, Julia Beck, Ekkehard Schütz, Howard B. Urnovitz and Donald P. Braun and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ashish Sangal

17 papers receiving 460 citations

Peers

Ashish Sangal

ONCOL

PRM

IMMUN

Preeti K. Parhar United States

Seonggyu Byeon South Korea

Hayato Kawachi Japan

Michèle Orain Canada

Marco Russano Italy

Liusheng Wu China

D. Jaeger Germany

Takashi Ichimura Japan

Matías Chacón Argentina

Mignon-Denise Keyver-Paik Germany

Preeti K. Parhar United States

Ashish Sangal

187 ×0.6

ONCOL

227 ×1.1

PRM

171 ×1.3

53 ×0.7

IMMUN

83 ×1.2

Citations per year, relative to Ashish Sangal Ashish Sangal (= 1×) peers Preeti K. Parhar

Countries citing papers authored by Ashish Sangal

Since Specialization

Citations

This map shows the geographic impact of Ashish Sangal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashish Sangal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashish Sangal more than expected).

Fields of papers citing papers by Ashish Sangal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashish Sangal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashish Sangal. The network helps show where Ashish Sangal may publish in the future.

Co-authorship network of co-authors of Ashish Sangal

This figure shows the co-authorship network connecting the top 25 collaborators of Ashish Sangal. A scholar is included among the top collaborators of Ashish Sangal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashish Sangal. Ashish Sangal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kao, Chinghai, Minetta C. Liu, Lauren F. Alexander, et al.. (2025). Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases. Scientific Reports. 15(1). 6126–6126. 1 indexed citations

Kao, Johnny, et al.. (2024). Predicting long‑term survival following involved site radiotherapy for oligometastases. Oncology Letters. 27(2). 82–82.

Siddiqui, Sana, et al.. (2023). Personalized Palliative and Survivorship Care for Patients With Metastatic Cancer Treated With Radiation Therapy. Anticancer Research. 43(4). 1387–1395. 2 indexed citations

Kao, Johnny, et al.. (2023). Long-term disease-free survival following comprehensive involved site radiotherapy for oligometastases. Frontiers in Oncology. 13. 1267626–1267626.

Jain, Prantesh, Alan D. Hutson, Débora S. Bruno, et al.. (2023). Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.. Journal of Clinical Oncology. 41(16_suppl). TPS2677–TPS2677. 1 indexed citations

Kao, Johnny, et al.. (2021). Association of radiation dose intensity with overall survival in patients with distant metastases. Cancer Medicine. 10(22). 7934–7942. 7 indexed citations

Wagner, Michael J., Megan Othus, Sandip Pravin Patel, et al.. (2021). Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). Journal for ImmunoTherapy of Cancer. 9(8). e002990–e002990. 106 indexed citations

Wagner, Michael, Megan Othus, Sandip Pravin Patel, et al.. (2020). 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). SHILAP Revista de lepidopterología. A475–A475. 9 indexed citations

Ahn, Eugene R., Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.. (2020). Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 4(4). 757–766. 46 indexed citations

10.

Ahn, Eugene R., Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.. (2019). Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. Journal of Clinical Oncology. 37(15_suppl). 9041–9041. 7 indexed citations

11.

Prakash, Ravi, Madappa N. Kundranda, Jeffrey S. Weber, et al.. (2018). Liquid nitrogen spray cryotherapy for dysphagia palliation in patients with inoperable esophageal cancer. Gastrointestinal Endoscopy. 88(3). 447–455. 29 indexed citations

12.

Weiss, Glen J., Julia Beck, Donald P. Braun, et al.. (2017). Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. Clinical Cancer Research. 23(17). 5074–5081. 113 indexed citations

13.

Weiss, Glen J., Sara A. Byron, Jessica Aldrich, et al.. (2017). A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. PLoS ONE. 12(6). e0179170–e0179170. 8 indexed citations

14.

Weiss, Glen J., Lisa Blaydorn, Ashish Sangal, et al.. (2017). A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). British Journal of Cancer. 117(1). 33–40. 101 indexed citations

15.

Weiss, Glen J., Donald P. Braun, Kirsten Bornemann-Kolatzki, et al.. (2016). Abstract 3138: Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research. 76(14_Supplement). 3138–3138. 5 indexed citations

16.

Weiss, Glen J., Julia Beck, Donald P. Braun, et al.. (2016). Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2.. Journal of Clinical Oncology. 34(15_suppl). 3027–3027. 3 indexed citations

17.

Weiss, Glen J., Robert P. Whitehead, Ashish Sangal, et al.. (2015). Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. OncoTargets and Therapy. 8. 959–959. 24 indexed citations

18.

Shah, Tilak, et al.. (2015). Tu1585 Cryotherapy in Combination With Systemic Chemotherapy for Gastro-Esophageal Cancer Palliation: Chilling Initial Results. Gastrointestinal Endoscopy. 81(5). AB519–AB519. 1 indexed citations

19.

Khalil, Maged, et al.. (2006). High Dose Glucocorticoids Potentiate the Reponse to Erythropoietin.. Blood. 108(11). 3775–3775. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact